Please use this identifier to cite or link to this item:
https://doi.org/10.3389/fphar.2014.00223
DC Field | Value | |
---|---|---|
dc.title | Prenatal transplantation of mesenchymal stem cells to treat osteogenesis imperfecta | |
dc.contributor.author | Chan, J.K.Y | |
dc.contributor.author | Götherström, C | |
dc.date.accessioned | 2020-10-27T11:12:24Z | |
dc.date.available | 2020-10-27T11:12:24Z | |
dc.date.issued | 2014 | |
dc.identifier.citation | Chan, J.K.Y, Götherström, C (2014). Prenatal transplantation of mesenchymal stem cells to treat osteogenesis imperfecta. Frontiers in Pharmacology 5 (OCT) : 223. ScholarBank@NUS Repository. https://doi.org/10.3389/fphar.2014.00223 | |
dc.identifier.issn | 16639812 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/181526 | |
dc.description.abstract | Osteogenesis imperfecta (OI) can be a severe disorder that can be diagnosed before birth. Transplantation of mesenchymal stem cells (MSC) has the potential to improve the bone structure, growth, and fracture healing. In this review, we give an introduction to OI and MSC, and the basis for pre- and postnatal transplantation in OI. We also summarize the two patients with OI who have received pre- and postnatal transplantation of MSC. The findings suggest that prenatal transplantation of allogeneic MSC in OI is safe. The cell therapy is of likely clinical benefit with improved linear growth, mobility, and reduced fracture incidence. Unfortunately, the effect is transient. For this reason, postnatal booster infusions using same-donor MSC have been performed with clinical benefit, and without any adverse events. So far there is limited experience in this specific field and proper studies are required to accurately conclude on clinical benefits of MSC transplantation to treat OI. © 2014 Chan and Götherström. | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | Unpaywall 20201031 | |
dc.subject | bisphosphonic acid derivative | |
dc.subject | allogeneic stem cell transplantation | |
dc.subject | allogenic bone marrow transplantation | |
dc.subject | alloimmunity | |
dc.subject | autosomal dominant inheritance | |
dc.subject | bone dysplasia | |
dc.subject | clinical effectiveness | |
dc.subject | compression fracture | |
dc.subject | engraftment | |
dc.subject | feasibility study | |
dc.subject | femur fracture | |
dc.subject | fetal stem cell | |
dc.subject | human | |
dc.subject | immunomodulation | |
dc.subject | mesenchymal stem cell | |
dc.subject | nonhuman | |
dc.subject | osteoblast | |
dc.subject | osteogenesis imperfecta | |
dc.subject | postnatal care | |
dc.subject | prenatal care | |
dc.subject | prenatal transplantation | |
dc.subject | Short Survey | |
dc.type | Others | |
dc.contributor.department | DUKE-NUS MEDICAL SCHOOL | |
dc.description.doi | 10.3389/fphar.2014.00223 | |
dc.description.sourcetitle | Frontiers in Pharmacology | |
dc.description.volume | 5 | |
dc.description.issue | OCT | |
dc.description.page | 223 | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_3389_fphar_2014_00223.pdf | 288.07 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License